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Abstract Monocyte-derived dendritic cells (moDCs) are in-
creasingly used in clinical settings to stimulate tumor immunity.
Prostaglandin E2 (PGE2), which is a member of the eicosanoid
family of oxygenated arachidonic acid derivatives generated
through the action of cyclooxygenases (COXs), is frequently
used to enhance the tumor necrosis factor-K-induced terminal
maturation of moDCs. We show here that one effect of
interleukin (IL)-4, which is used together with GM-CSF to
generate moDCs, is the suppression of endogenous PGE2
production in moDCs. IL-4 inhibits the cytoplasmic form of
phospholipase A2, the enzyme that specifically liberates arachi-
donic acid from membrane phospholipids. Although moDCs
failed to mobilize endogenous arachidonic acid, they converted
exogenous arachidonic acid into PGE2 in a COX-1- and COX-2-
dependent fashion. IL-4-mediated suppression of PGE2 bio-
synthesis in human moDCs explains the previously reported
maturation-enhancing effect of exogenous PGE2. The general
suppression of eicosanoid biosynthesis may, however, limit the
immunological efficacy of moDCs generated with IL-4. ß 2002
Published by Elsevier Science B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Dendritic cells (DCs) represent a small leukocyte subset
that appears to play a central role in the immune system
(reviewed by Banchereau and Steinman [1]). DCs can induce
and modulate antigen-speci¢c immune responses. In vitro,
DCs can be di¡erentiated from CD14 monocytes in a two-
step culture system [2,3]. In the ¢rst step, GM-CSF and inter-
leukin (IL)-4 promote the di¡erentiation of immature mono-
cyte-derived DCs (moDCs). In the second step, pro-in£amma-
tory factors induce the terminal maturation of CD83
immunostimulatory moDCs. We and others have shown
that exogenous prostaglandin E2 (PGE2) can enhance the
tumor necrosis factor (TNF)-K-induced maturation of moDCs
[4,5]. MoDCs have been used in numerous clinical studies to
induce or enhance tumor immunity in cancer patients and in
some studies PGE2 was used along with TNF-K to generate
mature moDCs [6^8].
PGE2 is a member of the eicosanoid family of oxygenated
arachidonic acid derivatives [9]. The ¢rst step of PGE2 bio-
synthesis is the release of arachidonic acid from membrane
phospholipids by phospholipases such as phospholipase A2
(PLA2) [10]. Macrophages contain at least three di¡erent
PLA2s, which have no sequence homology: a cytosolic and
a secretory PLA2 (cPLA2 and sPLA2), which both require
Ca2 as well as a Ca2-independent PLA2 (iPLA2). cPLA2
is considered a highly speci¢c enzyme for arachidonic acid
and generates a major pool of arachidonic acid in response
to pro-in£ammatory factors [9,10]. Free arachidonic acid is
further metabolized towards PGH2 via PGG2 by two cyclo-
oxygenase (COX) isoforms [11]. COX-1 is expressed constitu-
tively in most cell types and generates PGs, which are required
for the maintenance of normal physiological functions. In
contrast, COX-2 is inducible and is thought to contribute to
prostaglandin formation at sites of in£ammation. PGE2 syn-
thase ¢nally converts PGH2 into PGE2 [12].
In the present report, we have investigated the ability of
moDCs to generate PGE2 from endogenous or exogenous
arachidonic acid.
2. Materials and methods
2.1. Material
Lipopolysaccharide (LPS) from Salmonella abortus equi and arachi-
donic acid were obtained from Sigma (Vienna, Austria). Indometha-
cin (Liometacen) was from Chiesi Farmaceutici S.p.a. (Parma, Italy).
NS-398 was obtained from Cayman Chemical Company (Ann Arbor,
MI, USA). Calcium ionophore A23187 was purchased from Sigma.
2.2. Generation of moDCs
DCs were generated from monocytes in the presence of GM-CSF
and IL-4 as described previously [2^4]. CD14 monocytes were a⁄n-
ity-puri¢ed from peripheral blood mononuclear cells using the MACS
CD14 isolation-kit (Miltenyi Biotec, Bergisch Gladbach, Germany)
according to the manufacturer’s instructions. Monocytes (1U106
cells) were subsequently cultured in 1 ml of RPMI 1640 supplemented
with 10% heat-inactivated fetal calf serum (FCS), 50 U/ml penicillin,
50 Wg/ml streptomycin, 2 mM L-glutamine, 0.1 mM non-essential
amino acids, 1 mM pyruvate, and 5U1035 M 2-mercaptoethanol
as well as 1000 U/ml of each GM-CSF and IL-4. Monocytes were
also cultured with GM-CSF alone (GM-MOs). Monocytes could
not be cultured with IL-4 alone. Cells were fed on day 2 with 1 ml
of fresh medium and the cytokines indicated. Day 5 moDCs or
GM-MOs were stimulated with LPS at the indicated concentrations
for 24^48 h.
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2.3. PGE2 measurement
PGE2 was measured by a radioimmunoassay (Biotrak1 PGE2
(125I) assay system, Amersham Pharmacia Biotech, UK) according
to the manufacturer’s instructions. Culture supernatants (0.5 ml)
were mixed with one volume of water:ethanol (1:4) and 10 Wl of
glacial acetic acid and applied to a Amprep C18 minicolumn, which
had been primed with ethanol (10% in water). PGE2 was eluted using
ethylacetate and dried under a stream of nitrogen. PGE2 was recon-
stituted in phosphate-bu¡ered saline (PBS), pH 7.0, containing 0.1%
gelatin. Methyl oximation reagent was added and derivation was per-
formed overnight at room temperature. In this assay, PGE2 present in
the test sample is converted by methyloxiamine hydrochloride to the
stable methyl oximate derivative and competes with a ¢xed quantity
of 125I-labeled PGE2 tracer (methyl oximate derivative) for the limited
number of binding sites of an antiserum speci¢c for the methyl oxi-
mate derivative of PGE2. An aliquot of the processed test sample was
mixed with tracer and antiserum in assay bu¡er and incubated for 2 h
at 25‡C in a water bath. The antibody-bound fraction was separated
using magnetic separation. After 15 min separation on an Amerlex-M
separator base, the supernatants were discarded. Radioactivity present
in each tube was determined by counting for at least 60 s in a gamma
scintillation counter. The amount of PGE2 was calculated by compar-
ing the percentage binding of the test sample with a standard curve.
2.4. Western blotting analysis
On day 5, the cells were treated with 100 ng/ml of LPS for 20 h.
Cells were harvested, washed two times with ice-cold PBS, lysed in
ice-cold bu¡er containing 50 mM Tris^HCl (pH 7.3), 5 mM EDTA,
50 mM NaCl, 5 mM Na4P2O7W10 H2O, 5 mM NaF, 5 mM Na3VO4,
2% Triton X-100, 1 mM PMSF, 5 Wg/ml aprotinin and 5 Wg/ml leu-
peptin. Lysates were left on ice for 10 min and were subsequently
clari¢ed by centrifugation at 10 000 rpm for 15 min at 4‡C. Super-
natants were collected and 20 Wg of proteins was separated on an 8%
SDS^PAGE and transferred to a PVDF membrane (Immobilon-P,
Millipore). After blocking in 1% non-fat dry milk, TBST membranes
were incubated with anti-cPLA2 antibody (4-4B-3C, Santa Cruz Bio-
technology) followed by horseradish peroxidase-conjugated goat anti-
mouse IgG, washed and developed with enhanced chemoluminescence
(ECL Western blotting kit, Amersham Life Sciences).
2.5. Immunoprecipitation
cPLA2 was immunoprecipitated using rabbit polyclonal anti-cPLA2
antibody (N-216, Santa Cruz Biotechnology) and Protein A Micro-
Beads according to the manufacturer’s instructions (Miltenyi Biotech,
Bergisch Gladbach, Germany). Immunoprecipitated proteins were
separated on an 8% SDS^PAGE and transferred to a PVDF mem-
brane. Immunostaining was performed using an anti-phosphotyrosine
(PY20; Santa Cruz Biotechnology, CA, USA) or an anti-phosphoser-
ine antibody (PSR-45; Sigma, Vienna, Austria) and the immunoreac-
tive band was visualized using ECL.
2.6. Measurement of [3H]arachidonic acid release
Radiolabeling of moDCs was performed by incubating day 5
moDCs with 0.5 WCi/ml [5,6,8,9,11,12,14,15-3H]arachidonic acid (spe-
ci¢c activity 100 Ci/mmol; NEN Life Science Products) overnight in
culture medium containing 1% FCS. [3H]Arachidonic acid that had
not been incorporated was removed by washing the cells four times
with culture medium containing 1% FCS. An aliquot of the labeled
cells was removed to determine the incorporated radioactivity by
scintillation counting. Incorporation of [3H]arachidonic acid was sim-
ilar in GM-MOs and moDCs. The labeled cells were then replated in
96-well plates (2U105 cells in 200 Wl) in culture medium containing
10% FCS before the addition of increasing concentrations of LPS (0^
1000 ng/ml). Supernatants were removed after 30 min and 20 h, re-
spectively, cleared by centrifugation and assayed for radioactivity by
liquid scintillation counting. Results are mean values þ S.D. of dupli-
cate measurements.
3. Results and discussion
To examine the ability of moDCs to produce PGE2 from
endogenous arachidonic acid, day 5 moDCs were stimulated
with increasing concentrations of LPS (0^1000 ng/ml) and
PGE2 was measured in culture supernatants after 48 h using
a radioimmunoassay. To study the role of IL-4, monocytes
were also cultured with GM-CSF alone (GM-MOs) [13].
While GM-MOs produced large amounts of PGE2 in re-
sponse to LPS stimulation (Fig. 1A), the PGE2-producing
capacity was strongly diminished in moDCs (Fig. 1B) indicat-
ing that IL-4 suppresses PGE2 biosynthesis in human moDCs.
To determine whether liberation of arachidonic acid from
membrane phospholipids was limiting PGE2 production,
moDCs were matured with LPS for 48 h and then incubated
with exogenous arachidonic acid for 30 min. MoDCs con-
verted exogenous arachidonic acid into PGE2 in a dose-de-
pendent fashion (Fig. 1C). The non-selective COX inhibitor
indomethacin strongly blocked PGE2 formation by moDCs
from exogenous arachidonic acid (Fig. 1D), whereas the
COX-2-selective inhibitor NS-398 reduced PGE2 synthesis
by approximately 50% indicating that both isoforms contrib-
uted substantially.
Since cPLA2 is regulated by an increase in intracellular
calcium, which binds to an amino-terminal C2 domain and
induces its translocation to the nuclear envelope and endo-
plasmic reticulum [9], we also tested the in£uence of the highly
selective calcium ionophore A23187. However, A23187 failed
Fig. 1. IL-4 suppresses PGE2 production from endogenous arachi-
donic acid in human moDCs: conversion of exogenous arachidonic
acid into PGE2. A: Monocytes were cultured with GM-CSF alone
(GM-MOs) or (B) with GM-CSF plus IL-4 (moDCs). On day 5,
cells were stimulated with di¡erent concentrations of LPS. After
48 h, supernatants were harvested and analyzed for PGE2 contents.
C: After LPS-induced maturation for 48 h moDCs were harvested,
washed and resuspended in fresh medium (3U105 moDCs/ml) con-
taining arachidonic acid (AA) at the indicated concentrations. After
a 30 min incubation, the cells were centrifuged and PGE2 was mea-
sured in the supernatant. D: MoDCs were incubated for 30 min
with the non-selective COX inhibitor indomethacin (10 WM) or with
the COX-2-selective inhibitor NS-398 (10 WM) prior to the addition
of arachidonic acid. Results are from one experiment representative
of four independent experiments.
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to stimulate PGE2 production in GM-MOs and in moDCs,
respectively (not shown).
The failure to generate PGE2 from endogenous arachidonic
acid and the ability to convert exogenous arachidonic acid
into PGE2 suggested that moDCs were de¢cient in cPLA2
activity. Previous work has reported inhibitory e¡ects of IL-
4 on cPLA2 activity [14]. We therefore compared cPLA2 ex-
pression and activity in human moDCs (GM-CSF plus IL-4)
and in GM-MOs (GM-CSF only). Western blotting experi-
ments revealed that although cPLA2 protein could also be
detected in moDCs, the level of cPLA2 protein expression
was signi¢cantly reduced in moDCs as compared to GM-
MOs (Fig. 2A). Since cPLA2 activation has been shown to
require cPLA2 phosphorylation [15], we also used antibodies
directed against phosphotyrosine and phosphoserine to exam-
ine the phosphorylation state of cPLA2. For this purpose,
cPLA2 was immunoprecipitated from GM-MOs and moDCs,
respectively, and subjected to gel electrophoresis followed by
membrane blotting and staining for either phosphotyrosine
or phosphoserine. The comparatively weak phosphotyrosine
and phosphoserine staining of cPLA2 immunoprecipitated
from moDCs as compared to cPLA2 from GM-MOs (Fig.
2A) only re£ected the reduced level of cPLA2 in moDCs
but did not indicate a suppression of cPLA2 phosphorylation
by IL-4.
Finally, we compared the ability of radiolabeled moDCs to
liberate [3H]arachidonic acid in response to LPS stimulation.
Arachidonic acid mobilization by macrophages and mast cells
usually occurs in two phases [16]. The immediate phase, which
is characterized by a burst of arachidonic acid liberation,
takes minutes. The delayed phase, which spans several hours,
depends on the continuous supply of arachidonic acid and
involves cPLA2 activation. GM-MOs and moDCs incorpo-
rated similar amounts of [3H]arachidonic acid (approximately
20 000 cpm/2U105 cells). While GM-MOs induced the ex-
pected delayed arachidonic acid mobilization response, detect-
able at 20 h but not at 30 min, moDCs failed to mount a
similar response (Fig. 2B). Taken together, these data sug-
gested that only GM-MOs but not moDCs were able to in-
duce cPLA2 activity upon LPS stimulation and that IL-4
prevented the induction of cPLA2 protein and enzyme activ-
ity.
In conclusion, we have shown that IL-4 causes suppression
of PGE2 production in human moDCs. The failure of moDCs
to generate PGE2 also explains the previously reported e¡ects
of exogenous PGE2, which cooperates with TNF-K to pro-
mote the terminal maturation of CD83 immunostimulatory
moDCs [4,5]. PGE2 is both product and mediator of in£am-
mation in vivo. PGE2 plays a major role in tissue edema,
hyperalgesia and IL-6 production at sites of in£ammation
[17] and inhibitors of COX, the key enzyme in PGE2 produc-
tion, are used clinically to treat in£ammatory diseases [11].
Thus, it is tempting to argue that PGE2 also contributes to
DC activation in vivo.
Since cPLA2 appears to be a major target of the suppres-
sive e¡ect of IL-4, moDCs must probably also fail to generate
other arachidonic acid derivatives such as leukotrienes [9].
Spanbroek and colleagues recently demonstrated that IL-4
also suppresses 5-lipoxygenase in human moDCs [18]. Thus,
a double blockade induced by IL-4 appears to prevent leuko-
triene formation in moDCs. IL-4 prevents the liberation of
arachidonic acid by suppressing cPLA2 activity (Fig. 2). In
addition, IL-4 prevents the conversion of arachidonic acid
towards leukotrienes by suppressing 5-lipoxygenase [18].
However, leukotrienes may play an important role in DC
biology. Leukotriene C4 has been shown to be important
for the CCR7-directed migration of DCs to lymph nodes
[19] and leukotriene B4 plays a role in B [20] and natural
killer (NK) cell activation [21]. Thus, failure to produce leu-
kotrienes such as leukotriene B4 and C4 may hamper moDC
migration as well as the ability of moDCs to activate B and
NK cells [22].
Fig. 2. IL-4 suppresses cPLA2 protein expression and enzyme activ-
ity in human moDCs. Monocytes were cultured with GM-CSF
alone (GM-MOs) or with GM-CSF plus IL-4 (moDCs). A: Cells
were treated with 100 ng/ml of LPS for 20 h. Lysates (20 Wg) were
separated by SDS^PAGE and immunoblots were stained with an
anti-cPLA2 antibody. cPLA2 phosphorylation was examined after
immunoprecipitation. cPLA2 was immunoprecipitated from cell ex-
tracts using anti-cPLA2 antibodies, subjected to SDS^PAGE and
immunoblots were stained with an anti-phosphotyrosine antibody
(PY) or an anti-phosphoserine antibody (PS). B: GM-MOs or
moDCs were labeled with [3H]arachidonic acid. Similar amounts of
[3H]arachidonic acid were incorporated by GM-MOs and moDCs
(approximately 20 000 cpm per 2U105 cells). The LPS-induced re-
lease of arachidonic acid from GM-MOs (squares) and moDCs
(circles) was measured after 30 min (open symbols) and 20 h (closed
symbols). Results are mean values þ S.D. of duplicate measurements.
One out of three experiments with similar results is shown.
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